biostudies-literatureNgandu NKSouth African Medical Research CouncilWellcome TrustNational Department of Healthe058347https://www.ebi.ac.uk/biostudies/studies/S-EPMC8915310biostudies-literatureUnknown12(3)<h4>Objectives</h4>We aimed to measure the prevalence of maternal HIV viral load (VL) non-suppression and assess associated factors, to evaluate progress towards United Nations-AIDS (UNAIDS) targets.<h4>Design</h4>Cross-sectional study.<h4>Setting</h4>The eight largest community health centres of Ehlanzeni, a rural district in northeast South Africa.<h4>Participants</h4>Pregnant women living with HIV (WLHIV) in their third trimester and postpartum WLHIV and their biological infants, recruited equally across all stages of the first 24 months post partum, were included. A sample of 612 mothers participated from a target of 1000.<h4>Primary outcome measures</h4>The primary outcome was maternal VL (mVL) non-suppression (defined here as mVL >1000 copies/mL). We collected information on antiretrBMJ openHIV viral load non-suppression and associated factors among pregnant and postpartum women in rural northeastern South Africa: a cross-sectional survey.PMC8915310Not applicable222075/Z/20/ZNo grant number108065/Z/15/ZWaitt CVan de Perre PPrendergast AJMbira TEPuren ALombard CJNgandu NKTylleskar TGoga AEfalseHIV viral load non-suppression and associated factors among pregnant and postpartum women in rural northeastern South Africa: a cross-sectional survey.<h4>Objectives</h4>We aimed to measure the prevalence of maternal HIV viral load (VL) non-suppression and assess associated factors, to evaluate progress towards United Nations-AIDS (UNAIDS) targets.<h4>Design</h4>Cross-sectional study.<h4>Setting</h4>The eight largest community health centres of Ehlanzeni, a rural district in northeast South Africa.<h4>Participants</h4>Pregnant women living with HIV (WLHIV) in their third trimester and postpartum WLHIV and their biological infants, recruited equally across all stages of the first 24 months post partum, were included. A sample of 612 mothers participated from a target of 1000.<h4>Primary outcome measures</h4>The primary outcome was maternal VL (mVL) non-suppression (defined here as mVL >1000 copies/mL). We collected information on antiretr2022-01-01T00:00:00Z2022 Mar2025-04-19T00:53:18.198Z2025-04-07T11:48:13.754ZS-EPMC89153103527306110.1136/bmjopen-2021-058347